1. Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumour Biol. 2017 Jul;39(7).
2. Li, S., et al., Cancer immunotherapy via targeted TGF-β signalling blockade in T(H) cells. Nature, 2020. 587(7832): p. 121-125.
3. Dood, R.L., et al., Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncology, 2018. 4(11): p. 1519-1526.
4. Markman, M., et al., Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design. J Clin Oncol, 2004. 22(15): p. 3120-3125.
5. Anderson, K.S., et al., p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010. 19(3): p. 859-868.
6. Zhang, L., et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 2003. 348(3): p. 203-13.
7. Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i11-i15. .
8. Sabbatini, P.J., et al., Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res, 2007. 13(14): p. 4170-7.
9. O'Cearbhaill RE, Deng W, Chen LM, Lucci JA 3rd, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 Dec;155(3):393-399.
10. Burger, R.A., et al., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 2007. 25(33): p. 5165-71.
11. Garcia, A.A., et al., Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol, 2008. 26(1): p. 76-82.
12. Pujade-Lauraine, E., et al., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol, 2014. 32(13): p. 1302-8.
13. Li, Y.L., H. Zhao, and X.B. Ren, Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med, 2016. 13(2): p. 206-14.
14. Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7. doi: 10.1093/annonc/mdx444.
15. Institute, N.C., Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. U.S. Department of Health and Human Services, 2009.
16. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228-47.
17. Yao, T.J., C.B. Begg, and P.O. Livingston, Optimal sample size for a series of pilot trials of new agents. Biometrics, 1996. 52(3): p. 992-1001.
18. Aghajanian, C., et al., OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol, 2012. 30(17): p. 2039-45.
19. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007 Dec;6(12).
20. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012 Jul;59(1):145-55.
21. Pochechueva, T., Alam, S., Schötzau, A. et al. Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. J Ovarian Res 10, 8 (2017).
22. Smorodin EP, Sergeyev BL. The level of IgG antibodies reactive to TF, Tn and alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival. Exp Oncol. 2016 Jun;38(2):117-21.